ÂÜŔňÂŇÂ×

Dr. Pegram is currently the first Director of the Breast Cancer Oncology Program at Stanford Women’s Cancer Center in Stanford, California, and the Susy Yuan-Huey Professor of Oncology. He is also the co-Director of Stanford’s Molecular Therapeutics Program.

Dr. Pegram is a world-renown and recognized clinician and scholar in translational breast cancer research and a leader in translational medicine. He and his colleagues were instrumental in developing Herceptin as a treatment for Her2+ breast cancer and demonstrated efficacies by combining Herceptin with chemotherapies in pre-clinical experiments. Clinical trials conducted by Dr. Pegram and his colleagues demonstrated that Herceptin improved survival rates and even cured some breast cancer patients, representing a premier example of bench-to-bedside translational research. Dr. Pegram’s current research efforts continue to focus on the cancer-associated gene that encodes Her2 to develop new treatments to target these cancer cells as well as evaluate strategies to target estrogen receptors in breast cancers. Dr. Pegram has published more than 80 papers and conducted more than 20 clinical trials.